Kamada Granted Two Key Patents
Jun 24th 2013 8:36AM
Updated Jun 24th 2013 8:38AM
Kamada Granted Two Key Patents
Expands Protection for Company's Novel Respiratory Drug
NESS ZIONA, Israel--(BUSINESS WIRE)-- Kamada Ltd. (Nasdaq and TASE: KMDA) today announced that the Company was granted two key patents related to its novel Alpha-1 Antitrypsin (AAT) product to treat respiratory diseases. Kamada was granted Russian Patent No. 2472524, entitled "Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases," and an additional Australian Patent No. 2007213344 (co-owned with PARI PHARMA GMBH), entitled "Pulmonary delivery of Alpha-1 proteinase inhibitor."
These new patents continue to build upon Kamada's strong intellectual property portfolio for our family of AAT products to treat a variety of pulmonary diseases using inhaled AAT. The Australian patent underscores the novelty of the unique combination of inhaled AAT with the eFlow inhalation device. The newly issued Russian patent is related to the use of Kamada's inhaled AAT for the treatment of exacerbation events in different respiratory diseases. These two patents joins a family of patents that were already issued in different countries worldwide, including the U.S. and the European Union, as well as to currently pending patents which are expected to be issued.
"The inhaled AAT is currently in a late-stage clinical trial in Europe and Canada for the treatment of Alpha-1 Antitrypsin deficiency (AATD), a genetic disease that can cause serious, life threatening lung disease in adults," said David Tsur, the Chief Executive Officer of Kamada. "Securing global protection for our novel technologies and its various methods of use is critically important as we develop highly-purified AAT to address major unmet needs in various pulmonary diseases and advance toward commercial development."
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT has known and newly discovered therapeutic roles given its immuno-modulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. Kamada has nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil and other countries in Latin America, India, Eastern Europe and Asia. Kamada has five plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that is in pivotal Phase II/III clinical trials in Europe and Canada and will be entering Phase II clinical trials in the U.S. In addition, Kamada leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements that involve risks, uncertainties and assumptions, such as statements regarding the EMA and U.S. FDA marketing authorization of our Inhaled AAT for AATD, timing of clinical trials. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market, further regulatory delays. The forward-looking statements made herein speak only as of the date of this release and the Company undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
KEYWORDS: United States North America New York Middle East Israel
The article Kamada Granted Two Key Patents originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.